• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

触及不可及之处：难治性阿片类药物成瘾患者丙型肝炎病毒根除策略——一项真实世界经验

Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction-A Real-world Experience.

作者信息

Sandmann Lisa, Deppe Julian, Beier Christoph, Ohlendorf Valerie, Schneider Julia, Wedemeyer Heiner, Wedegärtner Felix, Cornberg Markus, Maasoumy Benjamin

机构信息

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany.

出版信息

Open Forum Infect Dis. 2021 Jun 17;8(8):ofab325. doi: 10.1093/ofid/ofab325. eCollection 2021 Aug.

DOI:10.1093/ofid/ofab325
PMID:34377724
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8339280/
Abstract

To achieve global hepatitis C virus (HCV) eradication, barriers prohibiting treatment access need to be overcome. We established a strategy to initiate antiviral therapy in patients with severe, refractory heroin addiction. All patients achieved sustained virological response. Outreach programs of hepatologists might be a reasonable way to overcome barriers to HCV treatment.

摘要

为实现全球丙型肝炎病毒（HCV）的根除，必须克服阻碍治疗可及性的障碍。我们制定了一项策略，对患有严重难治性海洛因成瘾的患者启动抗病毒治疗。所有患者均实现了持续病毒学应答。肝病专家的外展项目可能是克服HCV治疗障碍的合理方式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3a1/8339280/4c6ee6d1dd37/ofab325f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3a1/8339280/4c6ee6d1dd37/ofab325f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a3a1/8339280/4c6ee6d1dd37/ofab325f0001.jpg

相似文献

1
Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction-A Real-world Experience.触及不可及之处：难治性阿片类药物成瘾患者丙型肝炎病毒根除策略——一项真实世界经验
Open Forum Infect Dis. 2021 Jun 17;8(8):ofab325. doi: 10.1093/ofid/ofab325. eCollection 2021 Aug.
2
Direct-acting antiviral therapy for hepatitis C infection among people receiving opioid agonist treatment or heroin assisted treatment.直接作用抗病毒疗法治疗接受阿片类激动剂治疗或海洛因辅助治疗的丙型肝炎感染。
Int J Drug Policy. 2018 Dec;62:74-77. doi: 10.1016/j.drugpo.2018.10.003. Epub 2018 Oct 24.
3
Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.直接作用抗病毒药物清除丙型肝炎病毒可改善严重肝纤维化患者的颈动脉粥样硬化。
J Hepatol. 2018 Jul;69(1):18-24. doi: 10.1016/j.jhep.2018.02.015. Epub 2018 Mar 2.
4
Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.分散式与集中式药物替代方案中丙型肝炎的管理以及用于弥合丙型肝炎病毒治疗流程差距的微创即时检测
Swiss Med Wkly. 2017 Nov 20;147:w14544. doi: 10.4414/smw.2017.14544. eCollection 2017.
5
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.索磷布韦/维帕他韦/伏西瑞韦治疗既往接受过 DAA 治疗的慢性丙型肝炎患者的有效性和安全性。
J Hepatol. 2019 Oct;71(4):666-672. doi: 10.1016/j.jhep.2019.06.002. Epub 2019 Jun 14.
6
Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.直接作用抗病毒疗法治疗丙型肝炎：南非开普敦大学/格罗特舒尔医院肝脏诊所的初步经验。
S Afr Med J. 2020 Jan 29;110(2):112-117. doi: 10.7196/SAMJ.2020.v110i2.14195.
7
Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?直接作用抗病毒药物治疗接受阿片类药物替代治疗的慢性 HCV 感染患者：在临床实践中仍然令人担忧？
Addiction. 2018 May;113(5):868-882. doi: 10.1111/add.14128. Epub 2018 Jan 23.
8
Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.正在接受药物治疗的吸毒者和接受阿片类药物替代治疗者对直接作用抗病毒治疗的反应。
J Hepatol. 2019 Jul;71(1):45-51. doi: 10.1016/j.jhep.2019.02.018. Epub 2019 Mar 8.
9
Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.直接作用抗病毒药物清除丙型肝炎病毒后肝硬化患者的肝功能：来自 PITER 队列的数据。
BMC Infect Dis. 2021 May 4;21(1):413. doi: 10.1186/s12879-021-06053-3.
10
Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience.丙型肝炎病毒核酸检测阳性的实体器官移植物移植到丙型肝炎病毒阴性受者：真实世界的经验。
Hepatology. 2020 Jul;72(1):32-41. doi: 10.1002/hep.31011. Epub 2020 Apr 15.

引用本文的文献

1
[Strategietreffen: Virushepatitis in Deutschland eliminieren].[战略会议：在德国消除病毒性肝炎]
Z Gastroenterol. 2023 Feb;61(2):198-201. doi: 10.1055/a-1978-9021. Epub 2023 Feb 3.

本文引用的文献

1
Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R).直接作用抗病毒药物治疗慢性丙型肝炎病毒感染的真实世界疗效：仅部分改善健康相关生活质量——德国丙型肝炎注册研究（DHC-R）的结果。
J Viral Hepat. 2021 Aug;28(8):1206-1218. doi: 10.1111/jvh.13546. Epub 2021 Jun 8.
2
HCV micro-elimination in individuals with HIV in the Netherlands 4 years after universal access to direct-acting antivirals: a retrospective cohort study.荷兰在普遍获得直接作用抗病毒药物治疗 4 年后消除 HIV 合并 HCV 感染个体：一项回顾性队列研究。
Lancet HIV. 2021 Feb;8(2):e96-e105. doi: 10.1016/S2352-3018(20)30301-5. Epub 2020 Dec 22.
3
Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review.德国乙型、丙型和丁型肝炎的患病率：一项范围综述的结果
Front Public Health. 2020 Aug 28;8:424. doi: 10.3389/fpubh.2020.00424. eCollection 2020.
4
Clinical and Patient-Reported Outcomes of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C Among Patients on Opioid Agonist Treatment: A Real-world Prospective Cohort Study.阿片类激动剂治疗患者中直接作用抗病毒药物治疗慢性丙型肝炎的临床及患者报告结局：一项真实世界前瞻性队列研究
Open Forum Infect Dis. 2020 Aug 13;7(8):ofaa317. doi: 10.1093/ofid/ofaa317. eCollection 2020 Aug.
5
Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).在法国，接受直接作用抗病毒药物治疗的感染 HIV 的吸毒者和男男性行为者丙型肝炎治愈后的生活：定性和定量研究结果的健康认知和体验（ANRS CO13 HEPAVIH）。
J Viral Hepat. 2020 Dec;27(12):1462-1472. doi: 10.1111/jvh.13378. Epub 2020 Sep 24.
6
Introducing hepatitis C virus healthcare pathways in addiction care in the Netherlands with a Breakthrough project: a mixed method study.在荷兰的成瘾护理中引入丙型肝炎病毒医疗保健途径的突破项目：一项混合方法研究。
Harm Reduct J. 2019 Jul 15;16(1):45. doi: 10.1186/s12954-019-0316-4.
7
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.慢性丙型肝炎直接作用抗病毒治疗期间和治疗后的患者报告症状：PROP UP 研究。
J Hepatol. 2019 Sep;71(3):486-497. doi: 10.1016/j.jhep.2019.04.016. Epub 2019 May 13.
8
Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study.阿片类药物激动剂治疗医师对丙型肝炎病毒感染检测、管理和治疗相关认知障碍：C-SCOPE 研究。
J Viral Hepat. 2019 Sep;26(9):1094-1104. doi: 10.1111/jvh.13119. Epub 2019 Jun 11.
9
Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.接受阿片类激动剂治疗的注射吸毒者的丙型肝炎强化护理模式：一项随机对照试验。
Ann Intern Med. 2019 May 7;170(9):594-603. doi: 10.7326/M18-1715. Epub 2019 Apr 9.
10
Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.正在接受药物治疗的吸毒者和接受阿片类药物替代治疗者对直接作用抗病毒治疗的反应。
J Hepatol. 2019 Jul;71(1):45-51. doi: 10.1016/j.jhep.2019.02.018. Epub 2019 Mar 8.